Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Etelcalcetide (calcimimetic) for the Treatment of Secondary Hyperparathyroidism (SHPT)

Drug (Brand / Generic)

Etelcalcetide (calcimimetic)

Company

Amgen

Therapy Class

Calcimimetic therapy

Current Indication

Secondary hyperparathyroidism (SHPT)

Market Sector

Metabolic disorders

Development Status

Under review by FDA, MAA under review by European Medicines Agency (EMA)
Expand

Go Top